Sigma-Aldrich (R)-Butaprost. ≥98% (HPLC). 1 mg

(R)-Butaprost has been used as a prostanoid receptor (EP)-specific agonist to study its effects on protein kinase A (PKA) regulatory subunits in MCF7 cells.[1] It may be used as EP2 agonist in Madin-Darby canine kidney and mouse cortical collecting duct (mpkCCD14) cells.[2] It may also be used as EP2 agonist in human fetal lung fibroblasts (HFL-1) cells to test its effect on vascular endothelial growth factor (VEGF) production.[3]

(R)-Butaprost is a selective EP₂ prostanoid receptor agonist.

Butaprost comprises hydroxy-cyclopentanone ring and ω-chain.[4] It aids protection in events of glutamate based N-methyl-D-aspartate receptor toxicity.[5] Butaprost inhibits conjunctival fibrosis and lowers the intraocular pressure in post glaucoma filtration surgery.[6] It also promotes wound healing by reducing the subconjunctival scarring Tenon′s fibroblasts.[6] Butaprost plays a protective role in pulmonary fibrosis and aids protection against the aggregated amyloid β (Aβ) peptides in Alzheimer′s disease.[4]

This compound was developed by Bayer. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.